These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28198380)

  • 1. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
    Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
    Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
    Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
    Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
    Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
    Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the vulnerability to NAD
    Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
    Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
    Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
    Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
    Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
    Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NAMPT by PAK4 Inhibitors.
    Wang Y; Minden A
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
    Arowosegbe MA; Amusan OT; Adeola SA; Adu OB; Akinola IA; Ogungbe BF; Omotuyi OI; Saibu GM; Ogunleye AJ; Kanmodi RI; Lugbe NE; Ogunmola OJ; Ajayi DC; Ogun SO; Oyende FO; Bello AO; Ishola PG; Obasieke PE
    Curr Drug Discov Technol; 2020; 17(5):682-695. PubMed ID: 31441728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
    Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
    Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
    Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
    Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
    Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
    Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
    Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.
    Qasim SL; Sierra L; Shuck R; Kurenbekova L; Patel TD; Rajapakshe K; Wulff J; Nakahata K; Kim HR; Landesman Y; Unger TJ; Coarfa C; Yustein JT
    Oncogene; 2021 Feb; 40(6):1176-1190. PubMed ID: 33414491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
    Mohammad RM; Li Y; Muqbil I; Aboukameel A; Senapedis W; Baloglu E; Landesman Y; Philip PA; Azmi AS
    Small GTPases; 2019 Sep; 10(5):367-377. PubMed ID: 28641032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
    Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W
    Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells
    Jagadish N; Devi S; Gupta N; Suri V; Suri A
    Tumour Biol; 2020 Apr; 42(4):1010428320914477. PubMed ID: 32342732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.